Flexible-dose Long-term Extension Study of Lu AF11167 in Patients With Schizophrenia With Prominent Negative Symptoms

• Status: Terminated
• Trial end date: 2020-09-14
• Target enrollment: 0
• Participant gender: All

Summary

A study to evaluate the long-term safety and tolerability of flexible doses of Lu AF11167 in patients with schizophrenia during the 24-week treatment period

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: H. Lundbeck A/S

Criteria

Inclusion Criteria:

• The patient completed Study 17972A.

• The patient and the patient's caregiver or identified responsible person is able to read and understand the Informed Consent Form.

• The patient has signed the Informed Consent Form specific for Study 17972B.

• The patient can potentially benefit from 24 weeks of treatment with Lu AF11167 according to the investigator's clinical judgment.

Exclusion Criteria:

• The patient has any current primary psychiatric disorder other than schizophrenia diagnosed during study 17972A

• The patient, in the opinion of the investigator, is at significant risk of suicide

Other in- and exclusion criteria may apply